Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters
| Autor: | Israel Rubinstein, Hiroyuki Ikezaki, Hayat Onyuksel |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Mean arterial pressure Injections Subcutaneous Vasoactive intestinal peptide Pharmaceutical Science Hamster Blood Pressure Essential hypertension Cricetinae Internal medicine Heart rate Intubation Intratracheal medicine Animals Antihypertensive Agents Liposome business.industry medicine.disease Blood pressure Endocrinology Hypertension Liposomes Drug delivery business hormones hormone substitutes and hormone antagonists Vasoactive Intestinal Peptide |
| Zdroj: | International Journal of Pharmaceutics. 316:144-147 |
| ISSN: | 0378-5173 |
| DOI: | 10.1016/j.ijpharm.2006.02.028 |
| Popis: | We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1 nmol) administered by either routes normalizes MAP (p < 0.05). Maximal effect was observed within 10-20 min and lasted for 6 h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1 nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1 nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect